-+ 0.00%
-+ 0.00%
-+ 0.00%

Medivir's MIV-711 wins FDA rare pediatric disease designation for osteogenesis imperfecta

PUBT·11/19/2026 08:04:27
Listen to the news
Medivir's MIV-711 wins FDA rare pediatric disease designation for osteogenesis imperfecta
  • The FDA granted Medivir’s MIV-711 Rare Pediatric Disease Designation for osteogenesis imperfecta, strengthening its position ahead of a planned proof-of-concept study.
  • The study design is finalized and funding secured; MIV-711 already holds Orphan Drug Designation for the disease.
  • Previously reported animal research showed improved bone strength and quality; the planned study will assess the treatment in patients.
  • Marketing approval could qualify MIV-711 for a transferable Priority Review Voucher; vouchers sold for USD 180 million–USD 210 million in 2026.
  • Medivir estimates a minimum USD 2.5 billion market for treatments addressing underlying bone fragility in osteogenesis imperfecta, where none is currently approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medivir AB published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.